Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Go back to Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026| ENANTA PHARM (NASDAQ: ENTA) | Delayed: 14.54 +0.48 (3.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.06 | 52 Week High | $34.49 | |||
| Open | $14.08 | 52 Week Low | $20.39 | |||
| Day High | $14.70 | P/E | N/A | |||
| Day Low | $13.87 | EPS | $-3.18 | |||
| Volume | 29,392 | |||||
